<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drugDebug/PMC7095524/results/search/disease/results.xml">
  <result pre="UKLondon pmcid: 7095524360 doi: 10.1038/s41569-020-0360-5 : Comment COVID-19 and the" exact="cardiovascular" post="system http://orcid.org/0000-0003-0003-4270ZhengYing-Ying12http://orcid.org/0000-0001-5187-6625MaYi-Tongmyt_xj@sina.com3http://orcid.org/0000-0002-5284-2213ZhangJin-Yingjyzhang@zzu.edu.cn12http://orcid.org/0000-0002-0632-4626XieXiangxiangxie999@sina.com3[1], grid.412633.1Department of Cardiology, First Affiliated Hospital of"/>
  <result pre="the PMC Open Access Subset for unrestricted research re-use and" exact="secondary" post="analysis in any form or by any means with"/>
  <result pre="Health Organization (WHO) declaration of COVID-19 as a global pandemic." exact="Severe" post="acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infects host cells"/>
  <result pre="Organization (WHO) declaration of COVID-19 as a global pandemic. Severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV-2) infects host cells through"/>
  <result pre="(WHO) declaration of COVID-19 as a global pandemic. Severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV-2) infects host cells through ACE2"/>
  <result pre="declaration of COVID-19 as a global pandemic. Severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV-2) infects host cells through ACE2 receptors,"/>
  <result pre="2 (SARS-CoV-2) infects host cells through ACE2 receptors, leading to" exact="coronavirus disease" post="(COVID-19)-related pneumonia, while also causing acute myocardial injury and"/>
  <result pre="(SARS-CoV-2) infects host cells through ACE2 receptors, leading to coronavirus" exact="disease" post="(COVID-19)-related pneumonia, while also causing acute myocardial injury and"/>
  <result pre="receptors, leading to coronavirus disease (COVID-19)-related pneumonia, while also causing" exact="acute" post="myocardial injury and chronic damage to the cardiovascular system."/>
  <result pre="disease (COVID-19)-related pneumonia, while also causing acute myocardial injury and" exact="chronic" post="damage to the cardiovascular system. Therefore, particular attention should"/>
  <result pre="also causing acute myocardial injury and chronic damage to the" exact="cardiovascular" post="system. Therefore, particular attention should be given to cardiovascular"/>
  <result pre="the cardiovascular system. Therefore, particular attention should be given to" exact="cardiovascular" post="protection during treatment for COVID-19. Subject terms Infection Infectious"/>
  <result pre="given to cardiovascular protection during treatment for COVID-19. Subject terms" exact="Infection" post="Infectious diseases Cardiovascular diseases In December 2019, an outbreak"/>
  <result pre="to cardiovascular protection during treatment for COVID-19. Subject terms Infection" exact="Infectious" post="diseases Cardiovascular diseases In December 2019, an outbreak of"/>
  <result pre="Infectious diseases Cardiovascular diseases In December 2019, an outbreak of" exact="pneumonia" post="caused by a novel coronavirus occurred in Wuhan, Hubei"/>
  <result pre="pandemic1. After virus identification and isolation, the pathogen for this" exact="pneumonia" post="was originally called 2019 novel coronavirus (2019-nCoV)2 but has"/>
  <result pre="novel coronavirus (2019-nCoV)2 but has subsequently been officially named severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV-2) by the WHO. On"/>
  <result pre="coronavirus (2019-nCoV)2 but has subsequently been officially named severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV-2) by the WHO. On 30"/>
  <result pre="(2019-nCoV)2 but has subsequently been officially named severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV-2) by the WHO. On 30 January"/>
  <result pre="serious. Although the clinical manifestations of COVID-19 are dominated by" exact="respiratory" post="symptoms, some patients have severe cardiovascular damage3. In addition,"/>
  <result pre="COVID-19 are dominated by respiratory symptoms, some patients have severe" exact="cardiovascular" post="damage3. In addition, some patients with underlying cardiovascular diseases"/>
  <result pre="have severe cardiovascular damage3. In addition, some patients with underlying" exact="cardiovascular" post="diseases (CVDs) might have an increased risk of death3."/>
  <result pre="death3. Therefore, understanding the damage caused by SARS-CoV-2 to the" exact="cardiovascular" post="system and the underlying mechanisms is of the greatest"/>
  <result pre="a membrane-bound aminopeptidase that has a vital role in the" exact="cardiovascular" post="and immune systems4. ACE2 is involved in heart function"/>
  <result pre="in the cardiovascular and immune systems4. ACE2 is involved in" exact="heart" post="function and the development of hypertension and diabetes mellitus."/>
  <result pre="ACE2 is involved in heart function and the development of" exact="hypertension" post="and diabetes mellitus. In addition, ACE2 has been identified"/>
  <result pre="involved in heart function and the development of hypertension and" exact="diabetes mellitus." post="In addition, ACE2 has been identified as a functional"/>
  <result pre="a functional receptor for coronaviruses4, including SARS-CoV and SARS-CoV-2. SARS-CoV-2" exact="infection" post="is triggered by binding of the spike protein of"/>
  <result pre="the virus to ACE2, which is highly expressed in the" exact="heart" post="and lungs4. SARS-CoV-2 mainly invades alveolar epithelial cells, resulting"/>
  <result pre="expressed in the heart and lungs4. SARS-CoV-2 mainly invades alveolar" exact="epithelial" post="cells, resulting in respiratory symptoms. These symptoms are more"/>
  <result pre="and lungs4. SARS-CoV-2 mainly invades alveolar epithelial cells, resulting in" exact="respiratory" post="symptoms. These symptoms are more severe in patients with"/>
  <result pre="COVID-19 should be carefully considered. Whether patients with COVID-19 and" exact="hypertension" post="who are taking an ACE inhibitor or angiotensin-receptor blocker"/>
  <result pre="another antihypertensive drug remains controversial, and further evidence is required." exact="Acute" post="cardiac injury Reports suggest that the Middle East respiratory"/>
  <result pre="required. Acute cardiac injury Reports suggest that the Middle East" exact="respiratory" post="syndrome-related coronavirus (MERS-CoV) can cause acute myocarditis and heart"/>
  <result pre="that the Middle East respiratory syndrome-related coronavirus (MERS-CoV) can cause" exact="acute" post="myocarditis and heart failure5. SARS-CoV-2 and MERS-CoV have similar"/>
  <result pre="the Middle East respiratory syndrome-related coronavirus (MERS-CoV) can cause acute" exact="myocarditis" post="and heart failure5. SARS-CoV-2 and MERS-CoV have similar pathogenicity,"/>
  <result pre="Middle East respiratory syndrome-related coronavirus (MERS-CoV) can cause acute myocarditis" exact="and heart" post="failure5. SARS-CoV-2 and MERS-CoV have similar pathogenicity, and the"/>
  <result pre="East respiratory syndrome-related coronavirus (MERS-CoV) can cause acute myocarditis and" exact="heart" post="failure5. SARS-CoV-2 and MERS-CoV have similar pathogenicity, and the"/>
  <result pre="MERS-CoV have similar pathogenicity, and the myocardial damage caused by" exact="infection" post="with these viruses undoubtedly increases the difficulty and complexity"/>
  <result pre="suggesting that patients with severe symptoms often have complications involving" exact="acute" post="myocardial injury1. In addition, among the confirmed cases of"/>
  <result pre="myocardial injury1. In addition, among the confirmed cases of SARS-CoV-2" exact="infection" post="reported by the National Health Commission of China (NHC),"/>
  <result pre="the patients first went to see a doctor because of" exact="cardiovascular" post="symptoms. The patients presented with heart palpitations and chest"/>
  <result pre="a doctor because of cardiovascular symptoms. The patients presented with" exact="heart" post="palpitations and chest tightness rather than with respiratory symptoms,"/>
  <result pre="of cardiovascular symptoms. The patients presented with heart palpitations and" exact="chest" post="tightness rather than with respiratory symptoms, such as fever"/>
  <result pre="presented with heart palpitations and chest tightness rather than with" exact="respiratory" post="symptoms, such as fever and cough, but were later"/>
  <result pre="the NHC, 11.8% of patients without underlying CVD had substantial" exact="heart" post="damage, with elevated levels of cTnI or cardiac arrest"/>
  <result pre="had substantial heart damage, with elevated levels of cTnI or" exact="cardiac arrest" post="during hospitalization. Therefore, in patients with COVID-19, the incidence"/>
  <result pre="during hospitalization. Therefore, in patients with COVID-19, the incidence of" exact="cardiovascular" post="symptoms is high, owing to the systemic inflammatory response"/>
  <result pre="the incidence of cardiovascular symptoms is high, owing to the" exact="systemic" post="inflammatory response and immune system disorders during disease progression."/>
  <result pre="to the systemic inflammatory response and immune system disorders during" exact="disease" post="progression. The mechanism of acute myocardial injury caused by"/>
  <result pre="and immune system disorders during disease progression. The mechanism of" exact="acute" post="myocardial injury caused by SARS-CoV-2 infection might be related"/>
  <result pre="progression. The mechanism of acute myocardial injury caused by SARS-CoV-2" exact="infection" post="might be related to ACE2. ACE2 is widely expressed"/>
  <result pre="expressed not only in the lungs but also in the" exact="cardiovascular" post="system and, therefore, ACE2-related signalling pathways might also have"/>
  <result pre="therefore, ACE2-related signalling pathways might also have a role in" exact="heart" post="injury. Other proposed mechanisms of myocardial injury include a"/>
  <result pre="include a cytokine storm triggered by an imbalanced response by" exact="type 1" post="and type 2 T helper cells3,6, and respiratory dysfunction"/>
  <result pre="storm triggered by an imbalanced response by type 1 and" exact="type 2" post="T helper cells3,6, and respiratory dysfunction and hypoxaemia caused"/>
  <result pre="by type 1 and type 2 T helper cells3,6, and" exact="respiratory" post="dysfunction and hypoxaemia caused by COVID-19, resulting in damage"/>
  <result pre="hypoxaemia caused by COVID-19, resulting in damage to myocardial cells." exact="Chronic" post="cardiovascular damage A 12-year follow-up survey of 25 patients"/>
  <result pre="caused by COVID-19, resulting in damage to myocardial cells. Chronic" exact="cardiovascular" post="damage A 12-year follow-up survey of 25 patients who"/>
  <result pre="12-year follow-up survey of 25 patients who recovered from SARS-CoV" exact="infection" post="found that 68% had hyperlipidaemia, 44% had cardiovascular system"/>
  <result pre="from SARS-CoV infection found that 68% had hyperlipidaemia, 44% had" exact="cardiovascular" post="system abnormalities and 60% had glucose metabolism disorders7. Metabolomics"/>
  <result pre="history of SARS-CoV infection7. However, the mechanisms by which SARS-CoV" exact="infection" post="leads to disorders of lipid and glucose metabolism are"/>
  <result pre="similar structure to SARS-CoV, this novel virus might also cause" exact="chronic" post="damage to the cardiovascular system, and attention should be"/>
  <result pre="this novel virus might also cause chronic damage to the" exact="cardiovascular" post="system, and attention should be given to cardiovascular protection"/>
  <result pre="to the cardiovascular system, and attention should be given to" exact="cardiovascular" post="protection during treatment for COVID-19. Patients with pre-existing CVD"/>
  <result pre="COVID-19. Patients with pre-existing CVD A meta-analysis showed that MERS-CoV" exact="infection" post="was more likely to occur in patients with underlying"/>
  <result pre="occur in patients with underlying CVD8. In patients with MERS-CoV" exact="infection" post="and severe symptoms, 50% had hypertension and diabetes and"/>
  <result pre="In patients with MERS-CoV infection and severe symptoms, 50% had" exact="hypertension" post="and diabetes and up to 30% had heart disease."/>
  <result pre="with MERS-CoV infection and severe symptoms, 50% had hypertension and" exact="diabetes" post="and up to 30% had heart disease. Similarly, according"/>
  <result pre="50% had hypertension and diabetes and up to 30% had" exact="heart" post="disease. Similarly, according to the Pneumonitis Diagnosis and Treatment"/>
  <result pre="up to 30% had heart disease. Similarly, according to the" exact="Pneumonitis" post="Diagnosis and Treatment Program for New Coronavirus Infection (Trial"/>
  <result pre="to the Pneumonitis Diagnosis and Treatment Program for New Coronavirus" exact="Infection" post="(Trial Version 4), elderly people with comorbidities are more"/>
  <result pre="likely to be infected with SARS-CoV-2, especially those with hypertension," exact="coronary heart disease" post="or diabetes. Furthermore, patients with CVD are more likely"/>
  <result pre="to be infected with SARS-CoV-2, especially those with hypertension, coronary" exact="heart" post="disease or diabetes. Furthermore, patients with CVD are more"/>
  <result pre="be infected with SARS-CoV-2, especially those with hypertension, coronary heart" exact="disease" post="or diabetes. Furthermore, patients with CVD are more likely"/>
  <result pre="with severe symptoms of COVID-19, 58% had hypertension, 25% had" exact="heart" post="disease and 44% had arrhythmia1. According to mortality data"/>
  <result pre="severe symptoms of COVID-19, 58% had hypertension, 25% had heart" exact="disease" post="and 44% had arrhythmia1. According to mortality data released"/>
  <result pre="data released by the NHC, 35% of patients with SARS-CoV-2" exact="infection" post="had a history of hypertension and 17% had a"/>
  <result pre="35% of patients with SARS-CoV-2 infection had a history of" exact="hypertension" post="and 17% had a history of coronary heart disease."/>
  <result pre="a history of hypertension and 17% had a history of" exact="coronary heart disease." post="Furthermore, data show that patients aged &amp;gt;60 years who"/>
  <result pre="history of hypertension and 17% had a history of coronary" exact="heart" post="disease. Furthermore, data show that patients aged &amp;gt;60 years"/>
  <result pre="aged &amp;gt;60 years who were infected with SARS-CoV-2 had more" exact="systemic" post="symptoms and more severe pneumonia than patients aged ≤60"/>
  <result pre="infected with SARS-CoV-2 had more systemic symptoms and more severe" exact="pneumonia" post="than patients aged ≤60 years9. Therefore, in patients with"/>
  <result pre="in patients with SARS-CoV-2 infection, underlying CVD can aggravate the" exact="pneumonia" post="and increase the severity of symptoms. Patients with acute"/>
  <result pre="the pneumonia and increase the severity of symptoms. Patients with" exact="acute" post="coronary syndrome (ACS) who are infected with SARS-CoV-2 often"/>
  <result pre="and increase the severity of symptoms. Patients with acute coronary" exact="syndrome" post="(ACS) who are infected with SARS-CoV-2 often have a"/>
  <result pre="ACS, cardiac functional reserve can be reduced owing to myocardial" exact="ischaemia" post="or necrosis. When infected with SARS-CoV-2, cardiac insufficiency is"/>
  <result pre="high mortality. For patients with cardiac insufficiency who have underlying" exact="heart" post="disease, SARS-CoV-2 infection might act as a precipitating factor"/>
  <result pre="patients with cardiac insufficiency who have underlying heart disease, SARS-CoV-2" exact="infection" post="might act as a precipitating factor to worsen the"/>
  <result pre="factor to worsen the condition and lead to death. Drug-related" exact="heart" post="damage during COVID-19 treatment is a concern. In particular,"/>
  <result pre="antiviral drugs1. However, many antiviral drugs can cause cardiac insufficiency," exact="arrhythmia" post="or other cardiovascular disorders. Therefore, during treatment of COVID-19,"/>
  <result pre="many antiviral drugs can cause cardiac insufficiency, arrhythmia or other" exact="cardiovascular" post="disorders. Therefore, during treatment of COVID-19, especially with the"/>
  <result pre="specific mechanisms are uncertain. Patients with underlying CVD and SARS-CoV-2" exact="infection" post="have an adverse prognosis. Therefore, particular attention should be"/>
  <result pre="an adverse prognosis. Therefore, particular attention should be given to" exact="cardiovascular" post="protection during treatment for COVID-19. Related link Pneumonitis Diagnosis"/>
  <result pre="given to cardiovascular protection during treatment for COVID-19. Related link" exact="Pneumonitis" post="Diagnosis and Treatment Program for New Coronavirus Infection:http://www.gov.cn/zhengce/zhengceku/2020-01/28/content_5472673.htm Competing"/>
  <result pre="al.Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected" exact="pneumonia" post="in Wuhan, ChinaJAMA202010.1001/jama.2020.158532125371 2.ZhouPet al.A pneumonia outbreak associated with"/>
  <result pre="with 2019 novel coronavirus-infected pneumonia in Wuhan, ChinaJAMA202010.1001/jama.2020.158532125371 2.ZhouPet al.A" exact="pneumonia" post="outbreak associated with a new coronavirus of probable bat"/>
  <result pre="4.TurnerAJHiscoxJAHooperNMACE2: from vasopeptidase to SARS virus receptorTrends Pharmacol. Sci.20042529129410.1016/j.tips.2004.04.00115165741 5.AlhogbaniTAcute" exact="myocarditis" post="associated with novel Middle East respiratory syndrome coronavirusAnn. Saudi"/>
  <result pre="receptorTrends Pharmacol. Sci.20042529129410.1016/j.tips.2004.04.00115165741 5.AlhogbaniTAcute myocarditis associated with novel Middle East" exact="respiratory" post="syndrome coronavirusAnn. Saudi Med.201636788010.5144/0256-4947.2016.7826922692 6.WongCKet al.Plasma inflammatory cytokines and"/>
  <result pre="Pharmacol. Sci.20042529129410.1016/j.tips.2004.04.00115165741 5.AlhogbaniTAcute myocarditis associated with novel Middle East respiratory" exact="syndrome" post="coronavirusAnn. Saudi Med.201636788010.5144/0256-4947.2016.7826922692 6.WongCKet al.Plasma inflammatory cytokines and chemokines"/>
  <result pre="Saudi Med.201636788010.5144/0256-4947.2016.7826922692 6.WongCKet al.Plasma inflammatory cytokines and chemokines in severe" exact="acute" post="respiratory syndromeClin. Exp. Immunol.20041369510310.1111/j.1365-2249.2004.02415.x15030519 7.WuQet al.Altered lipid metabolism in"/>
  <result pre="Med.201636788010.5144/0256-4947.2016.7826922692 6.WongCKet al.Plasma inflammatory cytokines and chemokines in severe acute" exact="respiratory" post="syndromeClin. Exp. Immunol.20041369510310.1111/j.1365-2249.2004.02415.x15030519 7.WuQet al.Altered lipid metabolism in recovered"/>
  <result pre="after infectionSci. Rep.20177911010.1038/s41598-017-09536-z28831119 8.BadawiARyooSGPrevalence of comorbidities in the Middle East" exact="respiratory" post="syndrome coronavirus (MERS-CoV): a systematic review and meta-analysisInt. J."/>
  <result pre="infectionSci. Rep.20177911010.1038/s41598-017-09536-z28831119 8.BadawiARyooSGPrevalence of comorbidities in the Middle East respiratory" exact="syndrome" post="coronavirus (MERS-CoV): a systematic review and meta-analysisInt. J. Infect."/>
  <result pre="a systematic review and meta-analysisInt. J. Infect. Dis.20164912913310.1016/j.ijid.2016.06.01527352628 9.ChanJFet al.A" exact="familial" post="cluster of pneumonia associated with the 2019 novel coronavirus"/>
  <result pre="and meta-analysisInt. J. Infect. Dis.20164912913310.1016/j.ijid.2016.06.01527352628 9.ChanJFet al.A familial cluster of" exact="pneumonia" post="associated with the 2019 novel coronavirus indicating person-to-person transmission:"/>
  <result pre="person-to-person transmission: a study of a family clusterLancet202039551452310.1016/S0140-6736(20)30154-931986261 10.SakabeMYoshiokaRFujikiASick sinus" exact="syndrome" post="induced by interferon and ribavirin therapy in a patient"/>
  <result pre="induced by interferon and ribavirin therapy in a patient with" exact="chronic hepatitis" post="CJ. Cardiol. Cases2013817317510.1016/j.jccase.2013.08.00230534284"/>
  <result pre="by interferon and ribavirin therapy in a patient with chronic" exact="hepatitis" post="CJ. Cardiol. Cases2013817317510.1016/j.jccase.2013.08.00230534284"/>
 </snippets>
</snippetsTree>
